Veradermics MANE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$27.23M-120% | —— | —— | —— | -$12.4M-87.3% | ||
| $5.26M+2,369% | —— | —— | —— | $213K+241% | ||
| -$1.06M-53.8% | —— | —— | —— | -$686K-525% | ||
| -$1.37M-59.3% | —— | —— | —— | -$862K-371% | ||
| $174K— | —— | —— | —— | $0-100% | ||
| -$8K-14.3% | —— | —— | —— | -$7K— | ||
| —— | -$10.75K+92.5% | -$10.75K+92.5% | -$10.75K+92.5% | -$10.75K+92.5% | ||
| -$21.17M-59.0% | —— | —— | —— | -$13.32M-125% | ||
| $0-100% | —— | —— | —— | $19K— | ||
| $122.99M+682% | —— | —— | —— | $15.73M— | ||
| —— | $6.25M— | $6.25M— | $6.25M— | $6.25M— | ||
| -$101.3M-543% | —— | —— | —— | -$15.75M— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $11K— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | —— | $8.42M— | ||
| $269.11M+3,095% | —— | —— | —— | $8.42M-44.3% | ||
| $146.65M+810% | —— | —— | —— | -$20.64M-324% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $73K+462% | —— | —— | —— | $13K— | ||
| —— | $161.75K— | $161.75K— | $161.75K— | $161.75K— | ||
| $1.5M— | —— | —— | —— | $0— | ||
| -$4.36M-5,419% | —— | —— | —— | -$79K-127% | ||
| -$6K-200% | —— | —— | —— | -$2K+98.6% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $621K+73.9% | —— | —— | —— | $357K+41.2% | ||
| $21.69M— | —— | —— | —— | $0— | ||
| —— | $111.75K+58.0% | $111.75K+58.0% | $111.75K+58.0% | $111.75K+58.0% | ||
| $269.1M— | —— | —— | —— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$584K— | —— | —— | —— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $0-100% | —— | —— | —— | $90K— | ||
| —— | $4.2M— | —— | —— | —— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$21.17M-58.7% | —— | —— | —— | -$13.34M-125% | ||
| -$21.17M-58.7% | —— | —— | —— | -$13.34M-125% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Veradermics generate?
- Veradermics (MANE) generated -$46.3M in operating cash flow over the trailing twelve months.
- What is Veradermics 's free cash flow?
- After $19.0K of capital expenditures, Veradermics 's free cash flow was -$46.3M over the trailing twelve months.
- Where does Veradermics 's cash flow data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.